• Hormonal contraception in minors and young women, the relationship with the outcomes of pregnancy and childbirth

Hormonal contraception in minors and young women, the relationship with the outcomes of pregnancy and childbirth

HEALTH OF WOMAN. 2017.4(120):86–92; doi 10.15574/HW.2017.120.86

Veropotvelyan P. N., Radchenko V. V., Pivneva N. V., Osadchuk E. G.
«Interregional Center of Medical Genetics and Prenatal Diagnosis», Krivoy Rog
FPЕ Dnepropetrovsk Medical Academy, Krivoy Rog
«Center for Family Planning and Human Reproduction», Krivoi Rog

Pregnancy and childbirth among minors in need of attention of physicians of different specialties – psychologists, therapist, endocrinologists and obstetricians because of the high incidence of complications. Very important is the role of family planning and social care for minors and young women with secure information services and effective counseling in the aspect of improving the demographic situation in the country and the state of health of the population. Combined oral contraceptives are recommended in minors simultaneously using barrier contraception.

Key words: minor, contraception, pregnancy and childbirth complications.

REFERENCES

1. Lethaby A, Irvine GA, Cameron IT. 2008. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD001016.pub2

2. Fleming KL, Sokoloff A, Raine TR. 2010. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception 82(2):178–82. https://doi.org/10.1016/j.contraception.2010.02.020; PMid:20654760 PMCid:PMC3153421

3. Hooper DJ. 2010. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin. Drug Investig. 30(11):749–63. https://doi.org/10.2165/11538900-000000000-00000; PMid:20818837

4. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. 2012. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366(21):1998–2007. https://doi.org/10.1056/NEJMoa1110855; PMid:22621627

5. United Nations (UN). Proclamation of Teheran, Final Act of International Conference on Human Rights. Teheran, May13, 1968. U.N. Doc. A/CONF. 32/41 at 3 (1968). New York, United Nations. 1968.

6. Egarter C, Frey Tirri B, Bitzer J, Kaminskyy V, Oddens BJ, Prilepskaya V et al. 2013. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 13:9. Available at: http://www.ncbi.nlm.nih.gov/. https://doi.org/10.1186/1472-6874-13-9; PMid:23448283 PMCid:PMC3605181

7. Ersek JL, Brunner Huber LR, Thompson ME, Warren-Findlow J. 2011. Satisfaction and discontinuation of contraception by contraceptive method among university women. Matern. Child Health J. 15(4):497-506. https://doi.org/10.1007/s10995-010-0610-y; PMid:20428934

8. Moreau C, Cleland K, Trussell J. 2007. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 76(4):267–72. https://doi.org/10.1016/j.contraception.2007.06.008; PMid:17900435

9. Prilepskaya VN. 2014. Hormonal contraception. Clinical lectures. M, GEOTAR-Media:12–7.

10. Mihailin ES, Ivanova LA, Savitsky AG, Berlev IV. 2015. Legal consequences of pregnancy and labor in minors. Obstetrics and gynecology 17:63–67.

11. Dikke GB. 2015. Gormonalnaya contraceptives in young women – preferences, expectations, commitment. Obstetrics and gynecology 11:28–35.

12. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. The use of contraception outside the terms of the product licence. J Fam Plan Reprod Health Care. 2005. 31(3):225–242. https://doi.org/10.1783/1471189054483780; PMid:16105289

13. Kuznetsova IV. 2016. Metabolic effects of combined hormonal contraception and the risk of thrombotic oslojnenii. Obstetrics and Gynecology 6:108-114.

14. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 2013. 20 g versus >20 g estrogen combined oral contraceptives for contraception. (Review). Cochrane Database Syst. Rev. (8):CD003989. Available at: http: //onlinelibrary. wiley.com/. PMid:23904209

15. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. 2008. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 78(3):218–25. https://doi.org/10.1016/j.contraception.2008.05.004; PMid:18692612

16. Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. 2009. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80(5):436–44. https://doi.org/10.1016/j.contraception.2009.03.018; PMid:19835717

17. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. 1995. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab. 80(6):1816–21. https://doi.org/10.1210/jcem.80.6.7775629; https://doi.org/10.1210/jc.80.6.1816

18. Losert W, Casals-Stenzel J, Buse M. 1985. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 35(2):459–71. PMid:4039568

19. Nakajima ST, Archer DF, Ellman H. 2007. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin 24 Fe). Contraception 75(1):16-22. https://doi.org/10.1016/j.contraception.2006.08.004; PMid:17161118

20. Karahalis LY, Zhigalenko AR, Steblo EI. 2015. Contraceptive and non-contraceptive effects of drospirenone. Reproductive health of children and adolescents 2:73-7.

21. Willis SA, Kuehl TJ, Spikerman AM, Sulak PJ. 2006. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74(2):100-3. https://doi.org/10.1016/j.contraception.2006.02.006; PMid:16860046

22. Caiyan W, Wen D, Qinping L, Huan S, Ziyan H, Liangdan T et al. 2014. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi. 49(5):355–9. PMid:25030732

23. Fu Y, Mi W, Li L, Zhang H, Wang J, Cheng W et al. 2014. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi. 49(7):506–9. PMid:25327732

24. Mansour D, Verhoeven C, Sommer W, Weisberg E, Taneepanichskul S, Melis GB et al. 2011. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept. Reprod. Health Care 16(6):430–43. https://doi.org/10.3109/13625187.2011.614029

25. Gevorgyan MA, Manukhin IB, Tikhomirov AL, Kuznetsova EM. 2011. Experience in the use of drospirenone-containing hormonal contraceptives. Russian Medical Journal 19(1):24-33.

26. Prilepskaya VN, Novikova EP. 2012. Drospirenone-containing contraceptives – the possibilities are expanding. Farmateka 12:49–52.

27. Tikhomirov AL. 2014. Combination composition and demand for hormonal contraception. Russian Medical Journal 22(1):38–40.

28. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. 2014. Combination contraceptives: effects on weight. Review. Cochrane Database Syst. Rev. (1):CD003987. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD003987.pub5

29. Krattenmacher R. 2000. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 62(1):29–38. https://doi.org/10.1016/S0010-7824(00)00133-5

30. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. 2000. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care 5(2):124–34. https://doi.org/10.1080/13625180008500387

31. Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gulmezoglu AM. 2011. Types of progestogens in combined oral contraception: effectiveness and side-effects. (Review). Cochrane Database Syst. Rev. (5):CD004861. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD004861.pub2

32. Nappi RE, Albani F, Tonani S, Santamaria V, Pisani C, Terreno E et al. 2009. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct. Neurol. 24(2):71–5. PMid:19775533

33. Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A et al. 2003. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Health Care 8(1):37–51. https://doi.org/10.1080/ejc.8.1.37.51; https://doi.org/10.1080/713604397; PMid:12725674

34. Gruber DM, Huber JC, Melis GB, Stagg C, Parke S, Marr J. 2006. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 µg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 µg and desogestrel 150 mug. Treat. Endocrinol. 5(2):115–21. https://doi.org/10.2165/00024677-200605020-00005; PMid:16542051

35. Marr J, Heinemann K, Kunz M, Rapkin A. 2011. Ethinylestradiol 20 µg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int. J. Gynaecol. Obstet. 113(2):103-7. https://doi.org/10.1016/j.ijgo.2010.10.029; PMid:21338987

36. Rapkin AJ. 2008. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 53(9):729–41. PMid:18980045

37. Lopez LM, Kaptein AA, Helmerhorst FM. 2012. Oral contraceptives containing drospirenone for premenstrual syndrome. Review. Cochrane Database Syst. Rev. (2):CD006586. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD006586.pub4

38. Wong CL, Farquhar C, Roberts H, Proctor M. 2009. Oral contraceptive pill for primary dysmenorrhoea. Review. Cochrane Database Syst. Rev. (4):CD002120. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD002120.pub3; https://doi.org/10.1002/14651858.CD002120.pub2

39. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. 2012. Combined oral contraceptive pills for treatment of acne. Review. Cochrane Database Syst. Rev. (7):CD004425. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD004425.pub5

40. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. 2002. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 69(4, Suppl.):2–15. PMid:12096825

41. Maloney JM, Dietze P Jr, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P. 2008. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet. Gynecol. 112(4):773–81. https://doi.org/10.1097/AOG.0b013e318187e1c5

42. Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J. 2008. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 77(4):249–56. https://doi.org/10.1016/j.contraception.2007.11.003; PMid:18342647

43. Artymuk NV, Bukreeva EL. 2015. Comparative evaluation of the effect of a combination of 3 mg of drospirenone and 20 or 30 mcg ethinyl estradiol to the skin condition and anthropometric indices. Farmateka 3:31–3.

44. Hodzhibayeva TY, Zaripov NN, Rakhimov MM. 2007. Features of preconception period at primapara women. Materials IX of the Russian forum «Mother and child». M:289

45. Krotin PN, Yur’ev VK, Kulikov AM. 2001. The reproductive potential of modern teenage girls and ways to preserve it. Gedeon Rihter v SNG. 3:5–8.

46. Mikhalin ES, Ivanova LA, Savitsky AG, Berlev IV. 2016. Comparative characteristics of pregnancy and delivery complications in minor and middle reproductive-aged women. Russian Vestnik obstetrician-gynecologist 3(15):60–63. https://doi.org/10.17116/rosakush201616360-63

47. Sinchihin SP, Kokolina VF, Mamiev OB. 2004. Pregnancy and childbirth among minors. Pediatriya 3:93–96.

48. Ruedinger E, Cox JE. 2012. Adolescent childbearing: consequences and interventions. Curr Opin Pediatr 24;4:446–452. https://doi.org/10.1097/MOP.0b013e3283557b89

49. Rowlands S. 2010. Social predictors of repeat adolescent pregnancy and focussed strategies. Best Pract Res Clin Obstet Gynaecol 24;5:605–616. https://doi.org/10.1016/j.bpobgyn.2010.02.016; PMid:20363195

50. Ferraro AA, Cardoso VC, Barbosa AP. 2013. Childbearing in adolescence: intergenerational deja-vu? Evidence from a Brazilian birth cohort. BMC Pregnancy Childbirth 15:13–19. https://doi.org/10.1186/1471-2393-13-149

51. James AH. 2010. Obstetric management of adolescents with bleeding disorders. J Pediatr Adolesc Gynecol 23;6:31–37. https://doi.org/10.1016/j.jpag.2010.08.004; PMid:20934895

52. Malamitsi-Puchner A, Boutsikou T. 2006. Adolescent pregnancy and perinatal outcome. Pediatr Endocrinol Rev 3:170–171. PMid:16641854

53. Joshi М, Gumashta R. 2013. Weekly iron folate supplementation in adolescent girls-an effective nutritional measure for the management of iron deficiency anaemia. Glob J Health Sci 5;3:188–194. https://doi.org/10.5539/gjhs.v5n3p188

54. McCracken KA, Loveless M. 2014. Teen pregnancy: an update. Curr Opin Obstet Gynecol 26;5:355–359. https://doi.org/10.1097/GCO.0000000000000102; PMid:25136760

55. Pinzon JL, Jones VF. 2012. Care of adolescent parents and their children. Pediatrics 130;6:1743–1756. https://doi.org/10.1542/peds.2012-2879; PMid:23184113

56. Ganchimeg Т, Ota E, Morisaki N. 2014. Pregnancy and childbirth outcomes among adolescent mothers: a World Health Organization multicountry study. BJOG 121:40–48. https://doi.org/10.1111/1471-0528.12630; PMid:24641534

57. Paranjothy S, Broughton H, Adappa R. 2009. Teenage pregnancy: who suffers? Arch Dis Child 94;3:239–245. https://doi.org/10.1136/adc.2007.115915; PMid:19019886

58. Mikhailin ES, Ivanova LA. 2015. Specific features of teenage pregnancy and delivery in relation to age. Russian Vestnik obstetrician-gynecologist 2(15):68–74.